Disease-Vaccine-Landing-Page/Influenza/vaccine

Below are links to the U.S. Food & Drug Administration’s (FDA) website for the most current legally-required licensing information published in manufacturer package inserts for influenza vaccines available in the...

The majority of influenza vaccines were initially designated as Category B or C pharmaceutical products. This means that adequate and well-controlled studies on pregnant women were not conducted prior to...

A live-virus nasal flu vaccine, FluMist, was licensed by the FDA in June 2003 and initially approved use in healthy people between the ages of five and 49. It was...

In 2015, the FDA approved Fluad, the first adjuvanted trivalent flu vaccine containing a squalene oil adjuvant (MF59). This vaccine was approved for fast track licensure by the FDA, despite...

Cell-Based flu vaccines differ from standard egg-based flu vaccines because animal cells are used to grow the influenza virus. Currently only one cell-based flu vaccine, Flucelvax, is available in the...

The recombinant flu vaccine, approved for use in 2013, is manufactured through genetic engineering. It is produced using insect (armyworm) cells. Flublok is the only recombinant flu vaccine currently licensed...

The high-dose influenza vaccine, Fluzone, is approved for adults age 65 and older and contains four times the amount of antigen than the standard flu vaccine. This vaccine was given...

The most common flu vaccine is the inactivated (killed) influenza vaccine, which is prepared from the fluids of chick embryos inoculated with a specific type(s) of influenza virus. The...